Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
732 results about "High glucose" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
High blood sugar: An elevated level of the sugar glucose in the blood. Also called hyperglycemia. High blood sugar is a finding in a number of conditions, most notably diabetes mellitus.
Methods of determining pre or post meal time slots or intervals in diabetes management
A diabetes management system or process is provided herein that may be used to analyze and recognize patterns for a large number of blood glucose concentration measurements and other physiological parameters related to the glycemia of a patient. In particular, a method of monitoring glycemia in a patient may include storing a patient's data on a suitable device, such as, for example, a blood glucose meter. The patient's data may include blood glucose concentration measurements. The diabetes management system or process may be installed on, but is not limited to, a personal computer, an insulin pen, an insulin pump, or a glucose meter. The diabetes management system or process may identify a plurality of pattern types from the data including a testing / dosing pattern, a hypoglycemic pattern, a hyperglycemic pattern, a blood glucose variability pattern, and a comparative pattern. After identifying a particular pattern with the data management system or process, a warning message may be displayed on a screen of a personal computer or a glucose meter. Other messages can also be provided to ensure compliance of any prescribed diabetes regiments or to guide the patient in managing the patient's diabetes.
Owner:LIFESCAN INC
Method and device for utilizing analyte levels to assist in the treatment of diabetes
A health-monitoring device assesses the health of a user based on levels of two analytes in a biological fluid. A first analyte that is utilized to assess a user's health is a fat metabolism analyte, such as ketones, free fatty acids and glycerol, which is indicative of fat metabolism. A second analyte that is utilized is a glucose metabolism analyte, such as glucose. The levels of the two analytes may be used to assess insulin sensitivity, to detect both recent hypoglycemia and the cause of high glucose levels, and / or to guide therapeutic intervention. The dual analyte model may calculate a discrepancy between an actual insulin activity level and a theoretical insulin activity level. The dual analyte model of the present invention may be used to identify individuals at risk for metabolic syndrome, insulin resistance and non-insulin dependent diabetes, and allows monitoring of the progression of those disease states, as well as progress made by therapeutic interventions.
Owner:ABBOTT DIABETES CARE INC
Method, System and Computer Program Product for Evaluation of Blood Glucose Variability In Diabetes From Self-Monitoring Data
ActiveUS20090171589A1Long-term riskEnhance existing SMBG devicesHealth-index calculationMedical automated diagnosisLow glucoseRisk profiling
A system, computer program product, method and algorithm for evaluation of blood glucose variability—one of the most important parameters of diabetes management. An embodiment of the method may use routine self-monitoring blood glucose (SMBG) data collected over a period of 2-6 weeks, for example, based on a theory of risk analysis of blood glucose data. One aspect may include a method, system and computer program product for computing the Average Daily Risk Range (ADRR)—a measure of overall glucose variability. Another aspect may include a method, system, and computer program product for estimating separately the glucose variability in the hypoglycemic range via a Low BG Index (LBGI) and the glucose variability in the high BG range via High BG Index (HBGI) followed by a combination of the two indices into a single variability display.
Owner:UNIV OF VIRGINIA ALUMNI PATENTS FOUND
System and method to manage diabetes based on glucose median, glucose variability, and hypoglycemic risk
A system and method provides a glucose report for determining glycemic risk based on an ambulatory glucose profile of glucose data over a time period, a glucose control assessment based on median and variability of glucose, and indicators of high glucose variability. Time of day periods are shown at which glucose levels can be seen. A median glucose goal and a low glucose line provide coupled with glucose variability provide a view into effects that raising or lowering the median goal would have. Likelihood of low glucose, median glucose compared to goal, and variability of glucose below median provide probabilities based on glucose data. Patterns can be seen and provide guidance for treatment.
Owner:ABBOTT DIABETES CARE INC
Administration of insulin by jet injection
InactiveUS20060106362A1Easily employedHigh level of skillJet injection syringesMetabolism disorderInsulin dependentJet injection
The invention relates to a method for minimizing mean blood glucose levels in an insulin dependent patient by administering insulin to the patient in a sufficiently fast manner to provide a difference of 50% or less between high and low blood glucose levels. Advantageously, the insulin is administered to the patient by jet injection and the high and low blood glucose levels differ by an amount that is less than that which would be obtained after injection of insulin by a conventional needle syringe. The invention also relates to a method for reducing mean blood glucose levels in an insulin dependent patient that is receiving insulin through a conventional syringe and needle arrangement. This method provides for administration of the insulin to the patient by jet injection rather than by the syringe by substituting a jet injector for the syringe.
Owner:ANTARES PHARMA
Human glucagon-like peptide-1 mimics and their use in the treatment of diabetes and related conditions
InactiveUS20070287670A1Improve the level ofSenses disorderNervous disorderGlucagon-like peptide-1Drug biological activity
The present invention provides novel human glucagon-like peptide-1 (GLP-1) peptide mimics that mimic the biological activity of the native GLP-1 peptide and thus are useful for the treatment or prevention of diseases or disorders associated with GLP activity. Further, the present invention provides novel, chemically modified peptides that not only stimulate insulin secretion in type II diabetics, but also produce other beneficial insulinotropic responses. These synthetic peptide GLP-1 mimics exhibit increased stability to proteolytic cleavage making them ideal therapeutic candidates for oral or parenteral administration.
Owner:BRISTOL MYERS SQUIBB CO
Interpenetrating polymer network hydrogel corneal prosthesis
InactiveUS20070179605A1High tensile strengthHigh nutrient permeabilityNervous system cellsArtificial cell constructsCross-linkHydrophilic monomer
The present invention provides materials that have high glucose and oxygen permeability, strength, water content, and resistance to protein adsorption. The materials include an interpenetrating polymer network (IPN) hydrogel that is coated with biomolecules. The IPN hydrogels include two interpenetrating polymer networks. The first polymer network is based on a hydrophilic telechelic macromonomer. The second polymer network is based on a hydrophilic monomer. The hydrophilic monomer is polymerized and cross-linked to form the second polymer network in the presence of the first polymer network. In a preferred embodiment, the hydrophilic telechelic macromonomer is PEG-diacrylate or PEG-dimethacrylate and the hydrophilic monomer is an acrylic-based monomer. Any biomolecules may be linked to the IPN hydrogels, but are preferably biomolecules that support the growth of cornea-derived cells. The material is designed to serve as a corneal prosthesis.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV
Compositions for Preventing and Reducing Delayed Onset Muscle Soreness
InactiveUS20080317886A1Inhibit inflammationSpeed up recoveryBiocideSugar food ingredientsSucroseL glutamate
The present invention relates to the compositions that enhance post-exercise recovery processes to increase both strength and muscle mass, replace glycogen stores, and prevent inflammation, resulting in the prevention and / or reduction of delayed onset muscle soreness. Additionally, it provides a feeling of muscle relaxation as well as a feeling of mental tranquility immediately following exercise. The composition consists of any or all high-glycemic sugars and / or polysaccharides (e.g., sucrose, glucose, maltodextrin), all essential amino acids and beta-hydroxy-beta-methylbutyrate and can include other amino acids sources (e.g. whey protein), performance enhancing agents (e.g., caffeine, L-glutamate), anti-inflammatory agents (e.g., ginger, boswellia, curcumen), antioxidants (vitamin C, vitamin E, selenium, polyphenols,), insulin-mimicking agents (cinnamon, Banaba), analgesics (e.g. aspirin, ibuprofen, naproxen, acetaminophen), and to methods of treating humans and animals by administration of these novel compositions to humans and animals in need thereof.
Owner:SOUTHWEST IMMUNOLOGY
Multi-system therapy for diabetes, the metabolic syndrome and obesity
InactiveUS20050054731A1Symptoms improvedLower blood pressureBiocideDispersion deliveryLipid formationLipid lowering drug
A multi-system therapy which is adapted to treat diabetes, metabolic syndrome and obesity includes a hypoglycemic agent, a lipid lowering agent, a blood pressure lowering agent and, preferably, an anti-platelet agent. The composition can further include various vitamins and supplements such as vitamin B6, vitamin B12, arginin, a folate and other vitamins and minerals. Preferably, the hypoglycemic agent is a biguanide hypoglycemic agent without any additional hypoglycemic agent, making the composition suitable for treatment of individuals who are not hyperglycemic as well as those who are hyperglycemic.
Owner:FOLLI FRANCO +2
Lactobacillus reuteri and its application
ActiveCN107523526AImprove the level ofImprove triglyceridesMilk preparationNervous disorderDiseaseGut flora
The invention relates to the technical field of microorganism, and discloses a Lactobacillus reuteri and its application. The preservation number of the Lactobacillus reuteri CCFM8631 is CGMCC No.14394; the level of mice peripheral neurotransmitter 5-hydroxytryptamine can be significantlyimproved; the rise of the mice peripheral blood testonsterone level and the abundant abnormity of Blautia, Turicibacter, Oscillospira and Bifidobacterium in the intestinal flora by high glucose and high fatty diets are recovered; the tolerated simulative gastrointestinal fluid is rapidly planted in an intestinal tract, so as to significantly improve the pathological injury of metabolic syndrome mice liver and duodenum and rise of triglyceride and total cholesterol content in the serum by high glucose and high fatty diets are significantly improved; the Lactobacillus reuteri can be used for preventing, delaying or treating metabolic disorder such as metabolic syndrome, irritable bowel syndrome, and anxiety, depression and other metal diseases related to irritable bowel syndrome.
Owner:INFINITUS (CHINA) CO LTD
Yeast production culture for the production of butanol
High cell density cultures of yeast were found to have higher tolerance for butanol in the medium. The high cell density yeast cultures had greater survival and higher glucose utilization than cultures with low cell densities. Production of butanol using yeast in high cell density cultures is thus beneficial for improving butanol production.
Owner:BUTAMAXTM ADVANCED BIOFUELS
Wine brewing yeast strain and method for producing ethanol by efficient stalk fermentation
The invention discloses a Saccharomyces cerevisiae strain and a method for producing ethanol by fermenting stalks, the strain is Saccharomyces cerevisiae DQ1, the collection No. is CGMCC No.2528, the strain can tolerate methanoic acid, acetic acid and furfural type inhibitors in hydrolyzate of the stalks, tolerate high glucose concentration and ethanol concentration and have wide growth temperature, and the strain is fermented at high temperature; the method for producing the ethanol by fermenting the stalks comprises two-stage culture of seeds, wherein the first stage culture is carried out in a synthetic culture medium for 16-24 hours, the second stage culture is that a mixed culture medium containing 30-70 percent of hydrolyzate is inoculated into with the inoculation amount of 5-10 percent for culture for 15-20 hours, and the inoculation into the hydrolyzate with the inoculation amount of 10 percent or simultaneous saccharification and fermentation of the stalks is further carried out for producing the ethanol. The invention has the advantages of being applicable to high-solid-content stalk enzyme hydrolysis and simultaneous saccharification and fermentation, with short fermentation period, high ethanol yield, and low production cost, thereby having great industrial application prospect.
Owner:EAST CHINA UNIV OF SCI & TECH
Novel long-acting glucagon conjugate and pharmaceutical composition comprising the same for the prevention and treatment of obesity
ActiveUS20130122023A1Prolonged blood half-lifeImproved in vivo durabilityOrganic active ingredientsPeptide/protein ingredientsSide effectAdditive ingredient
Disclosed is a novel long-acting glucagon conjugate in which glucagon or its derivative is covalently linked to a polymer carrier via a non-peptide linker, and a pharmaceutical composition comprising the same as an effective ingredient useful for the prevention and treatment of obesity. Since the long-acting glucagon conjugate of the present invention shows improved in vivo durability and stability, when used in combination with an anti-obesity drug, it is possible to induce synergistic effects on the loss of body weight and decrease in food intake without causing any side-effects such as fluctuation in blood glucose level. Accordingly, the long-acting peptide conjugate of the present invention is very effective for the prevention and treatment of obesity.
Owner:HANMI SCI CO LTD
Bifidobacterium adolescentis and application thereof
InactiveCN107699517AImprove the level ofImprove oral glucose toleranceMilk preparationNervous disorderDiseaseIrritable bowel
The invention relates to the technical field of microorganisms, and discloses bifidobacterium adolescentis and an application thereof. The collection number of the bifidobacterium adolescentis CCFM8630 is CGMCC No.14395. The bifidobacterium adolescentis CCFM8630 has the advantages that the level of neurotransmitter 5-hydroxytryptamine in peripheral blood of rats can be remarkably upgraded by the bifidobacterium adolescentis CCFM8630; the increased level of hormones such as testosterone in the peripheral blood of the rats due to high-glucose and high-fat diet and anomaly of abundance of Blautiaand Turicibacter in intestinal floras of the rats can be recovered; simulated gastrointestinal fluid can be tolerated, the bifidobacterium adolescentis can be quickly colonized in intestinal tracts,accordingly, rat livers with metabolic syndromes, pathological injury of duodenums and increase of the contents of triglyceride and total cholesterol in serum due to the high-glucose and high-fat dietand oral glucose tolerance can be remarkably improved, and the bifidobacterium adolescentis can be used for preventing, relieving or treating metabolic disorder such as the metabolic syndromes, irritable bowel syndromes and psychological illnesses such as anxiety and depression which are related to the metabolic syndromes.
Owner:INFINITUS (CHINA) CO LTD
Method of screening remedy for diabetes
InactiveUS20030180813A1Promote insulin secretionReduce the amount of solutionFungiBacteriaConcentrations glucoseG protein-coupled receptor
A convenient screening tool and a convenient screening method for obtaining an agent for treating diabetes, a pharmaceutical composition for treating diabetes, and a process for manufacturing the pharmaceutical composition are disclosed. The screening tool is a G protein-coupled receptor, a variation functionally equivalent thereto, or a homologous polypeptide thereof which promotes insulin secretion under a high glucose concentration by activation, or cells transformed with an expression vector comprising a polynucleotide encoding the above polypeptide and expressing the polypeptide.
Owner:ASTELLAS PHARMA INC
Dynamic hepatic recycling glucose tolerance test
Systems and methods are described providing a hepatic recycling glucose tolerance test for the diagnosis of types and subtypes of diabetes mellitus and other hyperglycemic or hypoglycemic conditions. A method is also provided for screening candidate drugs for treating various types of abnormal glucose metabolism and to monitor whether the course of treatment is effective. The method also allows the correlation of gene activity, hormone and metabolite levels with glucose flux and recycling and an assessment of the degree of hepatic insulin resistance. The method utilizes a preferably non-radioactive stable labeled glucose to asses the relative rates of carbon flow in the liver and provides a hepatic recycling constant that is a measure of the relative rate of glucose recycling. The labeled glucose may be introduced to the patient orally, intravenously or by intraperitoneal administration for the desired effect.
Owner:RGT UNIV OF CALIFORNIA
Method of determining a potential of a hyperglycemic patients of developing vascular complications
Methods for determining a potential of a hyperglycemic patient to develop vascular complications in response to oxidative stress and for determining the importance of reducing oxidative stress in a specific hyperglycemic patient are disclosed. Each method includes the step of determining a haptoglobin phenotype of the patient. A variety of means of making this determination are further disclosed.
Owner:RAPPAPORT FAMILY INSTITUTE FOR RESEACH IN THE MEDICAL SCIENCES
Hydroxytyrosol and oleuropein compositions for induction of DNA damage, cell death and lsd1 inhibition
ActiveUS20140155339A1Improve antioxidant capacityBiocideHydroxy compound active ingredientsHydroxytyrosolDisease
Compositions comprising hydroxytyrosol-containing formulations and treatment regiments comprising hydroxytyrosol and / or oleuropein and chemotherapeutic agents are disclosed. Compositions and / or regiments may optionally include the administration of vitamins, minerals, and anti-oxidants. Methods for using these compositions and treatment regimens for treating subjects for diseases, such as a malignancy, and for inducing or enhancing angiogenesis, treating or preventing oxidative stress, for treating or preventing high glucose-induced dysfunction, treating or preventing chemotherapy-induced dysfunction, and for improving cell viability are provided. Various methods for use of the hydroxytyrosol compositions for inhibition of lysine specific demethylase 1 (LSD1) in various cancers are also provided.
Owner:MCCORD DARLENE E +1
Method of Treating Stress Hyperglycemia with Human Antibodies to the Glucagon Receptor
ActiveUS20130251728A1Easy to solveLower blood sugar levelsPeptide/protein ingredientsAntibody ingredientsDiseaseDiabetic ketoacidosis
The present invention provides antibodies that bind to the human glucagon receptor, designated GCGR and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human GCGR. The antibodies of the invention are useful for lowering blood glucose levels and blood ketone levels and are also useful for the treatment of diseases and disorders associated with one or more GCGR biological activities, including the treatment of diabetes, diabetic ketoacidosis, long-term complications associated with diabetes, or other metabolic disorders characterized in part by elevated blood glucose levels, including stress hyperglycemia.
Owner:REGENERON PHARM INC
Human adipose-derived stem cell serum-free basic medium
ActiveCN102732477BOvercome riskSkeletal/connective tissue cellsMineral ascorbatesAscorbic acid 2-sulfate
The invention discloses a human adipose-derived stem cell serum-free basic medium. The medium uses a serum substitute, and is composed of a high glucose type DMEM basic medium, human serum albumin, transferrin, taurine, reduced glutathione, ceruloplasmin, L-ascorbic acid-2-sulfate, alpha-tocopherol succinate, linoleic acid, alpha-ketoglutarate and selenium. The serum-free basic medium can exempt potential threats caused by animal serum in conventional serum-containing mediums to human health, and the adipose-derived stem cells cultured by the medium is more suitable for clinical application.
Owner:JIANGSU RE STEM BIOTECH
Brewing yeast strain, breeding method thereof, and application of the strain in alcohol production
InactiveCN101845404AWide growth temperature rangeGuaranteed normal fermentationFungiMutant preparationConcentrations glucoseAlcohol production
The invention discloses a brewing yeast strain, which has the classified name Saccharomyces cerevisiae Y09tj, and is preserved in Common Microorganism Center of China General Microbiological Culture Collection Center with the preservation number of CGMCC No.3476. The invention also provides a breeding method for the strain and a method for producing ethanol by quick high-temperature thick mash fermentation of starch. The strain is obtained by the following steps of: separating from common self-brewed sweet wine of peasant families; and performing ultraviolet mutagenesis for breeding. The brewing yeast strain CGMCC NO.3476 has the advantages of quick growth, strong fermentation capacity, high ethanol toxin resistance, and high-glucose concentration resistance of 62 percent (m / v) to the maximum. The average wine yield by the method is improved by 1.2 percent than that of other producing strains, and the wine yield can reach 16.0 percent (v / v); the fermentation period is short, and only 46 hours; the equipment utilization rate can be greatly improved; and the fermentation cost is greatly reduced.
Owner:GUANGXI ACAD OF SCI
Human adipose-derived stem cell serum-free basic medium
ActiveCN102732477AIncrease viscosityFree from mechanical damageSkeletal/connective tissue cellsAscorbic acid 2-sulfateMineral ascorbates
The invention discloses a human adipose-derived stem cell serum-free basic medium. The medium uses a serum substitute, and is composed of a high glucose type DMEM basic medium, human serum albumin, transferrin, taurine, reduced glutathione, ceruloplasmin, L-ascorbic acid-2-sulfate, alpha-tocopherol succinate, linoleic acid, alpha-ketoglutarate and selenium. The serum-free basic medium can exempt potential threats caused by animal serum in conventional serum-containing mediums to human health, and the adipose-derived stem cells cultured by the medium is more suitable for clinical application.
Owner:JIANGSU RE STEM BIOTECH
Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
ActiveUS8252321B2Improve performanceReduce the amount requiredHeavy metal active ingredientsBiocideDiseasePhytochemical
Owner:MORNINGSIDE VENTURE INVESTMENTS
Orally active fraction of momordica charactia, active peptides thereof, and their use in the treatment of diabetes
A water soluble extract of M.charantia named MC6, methods for its preparation and methods for its use in the treatment of hyperglycemic disorders are provided. The active MC6 is characterized by moving as a single band on SDS-PAGE having a molecular weight of less than 10 kDal, and by comprising three peptides. Also provided is a peptide component of MC6 named MC6.1, as well as analogues and mimetics thereof. The active MC6, MC 6.1, MC6.2, and MC6.3 exhibit hypoglycemic activity, even following oral administration. Also provided are methods of using the active agents to treat hyperglycemic disorders, particularly diabetes, where the active agents are preferably orally administered.
Owner:CALYX THERAPEUTICS
Peptides Derivatized with A-B-C-D- and their Therapeutical Use
The invention relates to protracted peptide derivatives such as Glucagon-Like Peptide-1 (GLP-1), exendin-4, and analogues thereof, as well as therapeutic uses thereof. The peptide derivative of the invention comprises a peptide wherein at least one amino acid residue is derivatized with A-B—C—, or A-B—C-D-. These compounds are useful in the treatment or prevention of diabetes type 2 and related diseases. The compounds are potent, have a low ratio of binding affinity to the GLP-1 receptor in the presence of high / low albumin concentrations, have long half-lives, and have a high affinity of binding to albumin, all of which is of potential relevance for the overall aim of achieving long-acting, stable and active GLP-1 derivatives with a potential for once weekly administration.
Owner:NOVO NORDISK AS
Method of determining a risk of hyperglycemic patients of developing a cardiovascular disease
A method and kit of evaluating a risk of a diabetic patient to develop cardiovascular disease (CVD) is disclosed. The method comprises determining a haptoglobin phenotype of the diabetic patient and thereby evaluating the risk of the diabetic patient to develop the cardiovascular disease (CVD), wherein the risk is decreased in diabetic patients with haptoglobin 1-1 phenotype as compared to patients with haptoglobin 1-2 or haptoglobin 2-2 phenotypes. The risk is also decreased in diabetic patients with haptoglobin 1-2 phenotype as compared to patients with haptoglobin 2-2 phenotype. The kit comprises packaged reagents for determining a haptoglobin phenotype of the diabetic patient and the kit is identified for use in evaluating a risk of a diabetic patient to develop cardiovascular disease (CVD).
Owner:RAPPAPORT FAMILY INSTITUTE FOR RESEACH IN THE MEDICAL SCIENCES
Recombined long-acting glucagons peptide analogue and preparation method thereof
ActiveCN101525387ABiologically activeImprove expression efficiencyFungiMicroorganism based processesHalf-lifeCurative effect
The invention relates to a recombined fusion protein, in particular discloses a recombined long-acting glucagons peptide analogue and a preparation method thereof. The long-acting glucagons peptide analogue is polypeptide by directly connecting duodenin analogue exendin-4 and human serum albumin, and no connecting peptide exists between the exendin-4 and the human serum albumin. The long-acting glucagons peptide analogue greatly prolongs the half-life of the exendin-4 and is clinically used to reduce the frequency of injection administration, lighten the suffering of patients, improve the curative effect and decrease the hospitalization cost.
Owner:NOVOPROTEIN SCI INC
Method and Device for Utilizing Analyte Levels to Assist in the Treatment of Diabetes
A health-monitoring device assesses the health of a user based on levels of two analytes in a biological fluid. A first analyte that is utilized to assess a user's health is a fat metabolism analyte, such as ketones, free fatty acids and glycerol, which is indicative of fat metabolism. A second analyte that is utilized is a glucose metabolism analyte, such as glucose. The levels of the two analytes may be used to assess insulin sensitivity, to detect both recent hypoglycemia and the cause of high glucose levels, and / or to guide therapeutic intervention. The dual analyte model may calculate a discrepancy between an actual insulin activity level and a theoretical insulin activity level. The dual analyte model of the present invention may be used to identify individuals at risk for metabolic syndrome, insulin resistance and non-insulin dependent diabetes, and allows monitoring of the progression of those disease states, as well as progress made by therapeutic interventions.
Owner:ABBOTT DIABETES CARE INC
Construction method of cynomolgus macaque model for alcoholic liver disease
InactiveCN106389394ABuild method time is shortIncrease success rateCompounds screening/testingHalogenated hydrocarbon active ingredientsHigh fatBiology
The invention belongs to a construction method of an animal model, and in particular relates to a construction method of a cynomolgus macaque model for alcoholic liver disease. The construction method of the cynomolgus macaque model for alcoholic liver disease comprises the following steps: screening experimental animals, feeding the screened experimental animals with high-glucose and high-fat feed, and conducting liver biopsy and acquisition of the determined model. The construction method of the cynomolgus macaque model for alcoholic liver disease provided by the invention is short in duration and high in success rate; the construction method is suitable for researching the occurrence mechanism of the alcoholic liver disease and is convenient for screening drugs for treating the alcoholic liver disease and for evaluating the efficacy of the drugs on the alcoholic liver disease; and the construction method has a good application prospect.
Owner:FANGCHENGGANG CHANGCHUN BIOLOGICAL TECH DEV
A high-sugar and low-protein tilapia feed
InactiveCN102265983AIncrease dosageLow in proteinFood processingClimate change adaptationRapeseedVitamin B6 synthesis
The invention discloses a high-sugar and low-protein tilapia feed. Based on the total mass fraction of 100%, it consists of the following components: fish meal: 0-3%, soybean meal: 16-20%, rapeseed meal: 18-21%, cotton meal: 12-16%, secondary meal: 39- 42%, soybean oil: 2-3%, choline chloride: 0.2-0.5%, sodium chloride: 0.1-0.5%, calcium dihydrogen phosphate: 1-2%, vitamin B1: 0.004-0.006%, vitamin B6: 0.002-0.004%, zinc sulfate: 0.02-0.04%, chromium chloride: 0.0001-0.0003%, vitamin premix: 0.1-0.2% and mineral premix: 0.5-1%. The invention maximizes the amount of secondary powder in the feed, adds several plant protein sources to overcome the problem of amino acid imbalance of a single protein source, and at the same time significantly reduces the amount of fish meal. By optimizing and adjusting the feed formula, supplementing suitable vitamin and mineral premixes to adjust the sugar utilization ability of tilapia, so that the tilapia can make good use of the sugar compound of the present invention, avoiding the damage of fish liver caused by high sugar, Fatty liver is formed, and even the fish body becomes obese, and the symptoms of "big belly" appear.
Owner:广东省农业科学院畜牧研究所 +1
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com